Vascular Cell Adhesion Molecule-l (VCAM-l) in Graves' Disease: Its Association to Thyroid Status and Thyroid Receptor Stimulating Antibodies

Abstract

Soluble vascular cell adhesion molecule-1 (sVCAM-1) and intercellular adhesion molecule-1 (sICAM-1) have been shown to be elevated in patients with Graves'disease and may play significant roles in the pathogenesis of the disease. The objective of this study was to measure the levels of sVCAM-1, sICAM-l, IL-6 and thyroid receptor stimulating antibodies (TRAb) in a cohort of hyperthyroid patients and determine their associations to thyroid hormones status, before and after 3 months thexapy with carbimazole. Materials and Methods: Patients were given fixed daily dose of 20 mg carbimazole for 3 months and blood samples were collected at baseline and end of the study. Thirty-eight patients were recruited from the Endocrine Clinic, Hospital Universiti Kebangsaan Malaysia, consisting of 26 females and 12 males, age ranging from 16 to 65 years. Blood samples collected before and at end of study were analysed for TSH, Free TJ, Free T4J thyroid receptor stimulating antibodies (TRAb), sVCAM-1, sICAM-1 and lL-6. Results: TRAb level of ?10 to U/L was taken to be negative, while TRAb level of >10 U/L was considered as positive. Twenty-six patients (68%) were TRAb positive (TRAb+) and 12 patients (30%) were TRAb negative (TRAb-). Median TRAb in TRAb+ patients was 23 UIL at baseline, declining to 16.7 U/L (p Conclusion: Compared to other inflammatory markers, sVCAM-l showed significant correlation to thyrOid stimulating antibodies and was most sensitive to changes in thyroid status. The significance of these findings in relation to Graves' disease warrants further investigation.